Abstract Background Patients with multiple myeloma (MM) were excluded from the original SARS-CoV-2 mRNA vaccine trials. which may influence vaccine hesitancy in this population. We prospectively characterized the safety and immunogenicity of two-dose SARS-CoV-2 mRNA vaccination in 44 patients with MM. who underwent vaccination from 12/17/2020 to 3/18/2021. https://www.bekindtopets.com/limited-price-Rx-Flunazine-flunixin-meglumine-Injectable-Solution-for-Horses-Cattle-best-mega/